This HTML5 document contains 113 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/company/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/pubchem-compound/
n8http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/drugbank/
n11http://www.rxlist.com/cgi/generic/
n15http://linked.opendata.cz/resource/drugbank/patent/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/national-drug-code-directory/
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n14http://www.drugs.com/cdi/
n12http://linked.opendata.cz/resource/drugbank/property/
n27http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB01260/identifier/chemspider/
n4http://linked.opendata.cz/resource/atc/
n3http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01260
rdf:type
n5:Drug
n5:description
A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem]
n5:dosage
n20:271B6055-363D-11E5-9242-09173F13E4C5 n20:271B6056-363D-11E5-9242-09173F13E4C5 n20:271B6057-363D-11E5-9242-09173F13E4C5 n20:271B6050-363D-11E5-9242-09173F13E4C5 n20:271B6051-363D-11E5-9242-09173F13E4C5 n20:271B6052-363D-11E5-9242-09173F13E4C5 n20:271B6053-363D-11E5-9242-09173F13E4C5 n20:271B6054-363D-11E5-9242-09173F13E4C5
n5:group
approved investigational
n5:indication
For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.
owl:sameAs
n8:DB01260 n9:DB01260
dcterms:title
Desonide
adms:identifier
n19:46506186 n21:5311066 n22:D03696 n23:0299-5770-60 n24:DB01260 n25:204734 n26:4470603 n28:PA164776996 n29:Desonide
n5:mechanismOfAction
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
n5:packager
n6:271B6037-363D-11E5-9242-09173F13E4C5 n6:271B603A-363D-11E5-9242-09173F13E4C5 n6:271B6035-363D-11E5-9242-09173F13E4C5 n6:271B6036-363D-11E5-9242-09173F13E4C5 n6:271B603D-363D-11E5-9242-09173F13E4C5 n6:271B603B-363D-11E5-9242-09173F13E4C5 n6:271B603C-363D-11E5-9242-09173F13E4C5 n6:271B6034-363D-11E5-9242-09173F13E4C5 n6:271B6038-363D-11E5-9242-09173F13E4C5 n6:271B6039-363D-11E5-9242-09173F13E4C5 n6:271B602E-363D-11E5-9242-09173F13E4C5 n6:271B602F-363D-11E5-9242-09173F13E4C5 n6:271B602C-363D-11E5-9242-09173F13E4C5 n6:271B602D-363D-11E5-9242-09173F13E4C5 n6:271B6032-363D-11E5-9242-09173F13E4C5 n6:271B6033-363D-11E5-9242-09173F13E4C5 n6:271B6030-363D-11E5-9242-09173F13E4C5 n6:271B6031-363D-11E5-9242-09173F13E4C5 n6:271B602B-363D-11E5-9242-09173F13E4C5
n5:patent
n15:6387383 n15:6730288
n5:synonym
Desonidum 11beta,21-Dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione Desfluorotriamcinolone acetonide 16alpha,17alpha-Isopropylidenedioxyprednisolone 11beta,21-Dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione 16alpha-Hydroxyprednisolone-16alpha,17-acetonide 16alpha-Hydroxyprednisole-16,17-acetonide Desonida 11beta,21-Dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
n3:hasAHFSCode
n13:84-06-00
n5:synthesisReference
Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.
foaf:page
n11:desonide.htm n14:desonide-cream.html n27:tri1457.shtml
n5:IUPAC-Name
n12:271B605C-363D-11E5-9242-09173F13E4C5
n5:InChI
n12:271B6062-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n12:271B6061-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n12:271B605E-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n12:271B605F-363D-11E5-9242-09173F13E4C5
n5:SMILES
n12:271B6060-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n12:271B6072-363D-11E5-9242-09173F13E4C5 n12:271B605A-363D-11E5-9242-09173F13E4C5
n5:logP
n12:271B6058-363D-11E5-9242-09173F13E4C5 n12:271B6074-363D-11E5-9242-09173F13E4C5 n12:271B605B-363D-11E5-9242-09173F13E4C5
n5:logS
n12:271B6059-363D-11E5-9242-09173F13E4C5
n3:hasATCCode
n4:D07AB08 n4:S01BA11
n5:H-Bond-Acceptor-Count
n12:271B6068-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n12:271B6069-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n12:271B6063-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n12:271B6064-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n12:271B6066-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n12:271B6065-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n12:271B6067-363D-11E5-9242-09173F13E4C5
n5:absorption
Topical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
638-94-8
n5:containedIn
n16:271B6047-363D-11E5-9242-09173F13E4C5 n16:271B6048-363D-11E5-9242-09173F13E4C5 n16:271B6045-363D-11E5-9242-09173F13E4C5 n16:271B6046-363D-11E5-9242-09173F13E4C5 n16:271B604B-363D-11E5-9242-09173F13E4C5 n16:271B604C-363D-11E5-9242-09173F13E4C5 n16:271B6049-363D-11E5-9242-09173F13E4C5 n16:271B604A-363D-11E5-9242-09173F13E4C5 n16:271B604F-363D-11E5-9242-09173F13E4C5 n16:271B604D-363D-11E5-9242-09173F13E4C5 n16:271B604E-363D-11E5-9242-09173F13E4C5 n16:271B603F-363D-11E5-9242-09173F13E4C5 n16:271B6040-363D-11E5-9242-09173F13E4C5 n16:271B603E-363D-11E5-9242-09173F13E4C5 n16:271B6043-363D-11E5-9242-09173F13E4C5 n16:271B6044-363D-11E5-9242-09173F13E4C5 n16:271B6041-363D-11E5-9242-09173F13E4C5 n16:271B6042-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n12:271B606E-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n12:271B6070-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n12:271B6071-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n12:271B6073-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n12:271B606D-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n12:271B606C-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n12:271B606F-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n12:271B605D-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n12:271B606A-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n12:271B606B-363D-11E5-9242-09173F13E4C5